Biotech Losesr: Endocyte (NASDAQ:ECYT), TG Therapeutics (NASDAQ:TGTX), Theravance Biopharma Inc (NASDAQ:TBPH), China Biologic Products Inc (NASDAQ:CBPO), Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)

Endocyte, Inc. (NASDAQ:ECYT)’s shares dropped 15.74% to $6.51. The company on June 17 announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Endocyte, Inc. (NASDAQ:ECYT), net profit margin is -25.40% and weekly performance is -2.50%. On last trading day company shares ended up $6.64. Analysts mean target price for the company is $15.50. Endocyte, Inc. (NASDAQ:ECYT), distance from 50-day simple moving average (SMA50) is -40.41%.

Investment analysts at Ladenburg Thalmann set a $18.00 target price on shares of TG TG Therapeutics, Inc. (NASDAQ:TGTX), stock in a note issued to investors on Monday. Ladenburg Thalmann’s target price would indicate a potential upside of 87.30% from the stock’s previous close. TG Therapeutics, Inc. (NASDAQ:TGTX), fell 6.58% in last trading session and ended the day on $8.24. TGTX, return on assets is -54.70%. TG Therapeutics, Inc. (NASDAQ:TGTX), quarterly performance is 12.72%.

Theravance and Theravance Biopharma Inc (NASDAQ:TBPH), have announced the completion of the separation of Theravance Biopharma, the research and development-based biopharmaceutical business, from Theravance. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders.Theravance Biopharma Inc (NASDAQ:TBPH), shares moved down 6.52% in last trading session and was closed at $30.66, while trading in range of $29.92 – 32.55. Theravance Biopharma Inc (NASDAQ:TBPH), year to date (YTD) performance is 33.54%.

China Biologic Products Inc (NASDAQ:CBPO), a leading plasma-based biopharmaceutical company in China, announced that it filed a preliminary prospectus supplement in connection with the commencement of a public offering of shares of its common stock. The Company plans on selling 1,000,000 shares of common stock and certain selling stockholders plan on selling 2,212,500 shares of common stock in the offering. In addition, the Company has granted the underwriters a 30-day option to purchase up to 481,875 additional shares of common stock. The final terms of the offering will depend on market and other conditions at the time of pricing. China Biologic Products Inc (NASDAQ:CBPO), ended the last trading day at $42.11. Company weekly volatility is calculated as 6.37% and price to cash ratio as 6.55. China Biologic Products Inc (NASDAQ:CBPO), showed a negative weekly performance of 12.55%.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is set to join the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), weekly performance is -10.78%. On last trading day company shares ended up $10.35. Analysts mean target price for the company is $18.00. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), distance from 50-day simple moving average (SMA50) is -9.65%.